Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 14

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study of Durvalumab for Patients with Early Stage or Locally Advanced Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ART6043
  • Sponsor:Artios Pharma Limited

Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides Farinae Extract
  • Sponsor:Inmunotek S.L.

Crohn's disease

Recruiting

Study of Mirikizumab for Children with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Long-Term Safety and Efficacy Study of Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Endometrial cancer+5

Recruiting

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.